Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can saltwater breathing ease a tough lung infection?

NCT ID NCT07647575

Symptom relief Sponsor: Taipei Veterans General Hospital, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether inhaling a salty mist (3% hypertonic saline) can improve breathing symptoms in people with nontuberculous mycobacterial (NTM) lung disease who haven't yet started antibiotics. About 262 adults will either start the saltwater treatment right away for 6 months or begin with normal saline for 3 months then switch. The main goal is to see if symptoms like cough and shortness of breath improve more with the stronger salt solution.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
3% hypertonic saline
What this could lead to
If it works, this could offer a simple, drug-free way to ease respiratory symptoms and improve mucus clearance in NTM lung disease.
What could go wrong
This is an early-stage trial with no phase designation, and the primary endpoint is symptom scores at just 3 months. The effect may be modest or not clinically meaningful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 262 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years or older. 2. Diagnosis of nontuberculous mycobacterial lung disease (NTM-LD) according to ATS/ERS/ESCMID/IDSA diagnostic criteria, including compatible clinical symptoms, radiographic findings, and microbiological evidence. 3. Not receiving anti-NTM antibiotic treatment at the time of screening. 4. Able and willing to provide written informed consent. 5. Able to perform nebulized inhalation therapy using a mesh nebulizer at home. Exclusion Criteria: 1. Active tuberculosis. 2. Human immunodeficiency virus (HIV) infection. 3. Receiving active treatment for malignancy. 4. Uncontrolled asthma. 5. Frequent or clinically significant hemoptysis. 6. History of intolerance, bronchospasm, or hypersensitivity during inhalation testing with hypertonic saline. 7. Inability to prepare a mesh nebulizer or perform inhalation therapy at home. 8. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchiectasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchiectasis Mycobacterium avium complex disease Mycobacterium Infections, Nontuberculous pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchiectasis Nontuberculous mycobacterial lung disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.